Table 2.
Clinical characteristics of hepatocellular carcinoma (HCC) patients.
| Mean ± SD | (n, %) | ||
|---|---|---|---|
| Tumor size (cm) | 5.7 + 5.1 | ||
| Number of tumors | |||
| Single | 117 | (49.80%) | |
| Two lesions | 33 | (14.00%) | |
| Multiple (≥3) | 85 | (36.20%) |
|
| Child-Turcotte-Pugh score | |||
| A | 135 | (57.40%) | |
| B | 75 | (31.90%) | |
| C | 25 | (10.60%) | |
| Portal vein thrombosis | 36 | (15.30%) | |
| Vascular invasion | 28 | (11.90%) | |
| Metastasis | 31 | (13.20%) | |
| Noncirrhotic liver | 44 | (18.70%) | |
| Liver transplant | 21 | (8.9%) | |
| MELD | 11 + 5 | ||
| Bilirubin, μmol/L | 41.5 ± 113 | ||
| Albumin, g/L | 34 ± 7 | ||
| AST, U/L | 96 ± 103 | ||
| ALT, U/L | 64 ± 59 | ||
| INR | 1.2 ± 0.4 | ||
| AFP | 10934.2 ± 48 | ||
| Platelets, ×109/L | 201 ± 135 | ||
| BCLC stages | |||
| Stage 0 (very early) | 8 | (3.4%) | |
| Stage A (early) | 79 | (33.6%) | |
| Stage B (intermediate) | 81 | (34.5%) | |
| Stage C (advanced) | 42 | (17.9%) | |
| Stage D (terminal) | 25 | (10.6%) | |
SD: standard deviation; MELD: model for end-stage liver disease; AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; BCLC: Barcelona Clinic Liver Cancer.